A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions

Healthy

Interventions

DRUG

Enlicitide decanoate

Oral tablet

Trial Locations (1)

Celerion (Site 0001), Lincoln

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06691906 - A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025) | Biotech Hunter | Biotech Hunter